Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

MeMed Secures $93M Financing To Commercialize Diagnostics Platform

Executive Summary

The company will use the money to fund its US commercialization strategy and continue to develop its host response-based product pipeline.

You may also be interested in...



Minute Insight: MeMed Announces Viral/Bacterial Infection Differentiation Results, Commercial Partnership

DiaSorin will distribute MeMed BV, a rapid point-of-care test that can differentiate bacterial and viral infections, under a new commercial agreement.

Exec Chat: MeMed Improves Diagnostics To Combat Antimicrobial resistance

Kfir Oved, co-founder and CTO of MeMed, talked to Medtech Insight about diagnostic testing that can differentiate bacterial and viral infections to fight antimicrobial resistance.

MeMed’s Mission: Pressing Its Fingerprint Against AMR

Approved in Europe and just given the US green light, MeMed is making waves in the fight against antimicrobial resistance using advanced "host response" technology. Its CEO talks to In Vivo about strategy, commercialization and earning the right to fantasize.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

MT144919

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel